

The Danish Cancer Society allocates DKK 15 million for research in faster and better detection, diagnostics, treatment and follow-up of cancer

There is a need to develop new and better offers for cancer patients within a broad spectrum of detection, diagnostics, treatment, and follow-up of cancer. Several examples in the area are mentioned below.

Tracking

The existing screening offers for colon, breast and cervical cancer lead to the detection of approximately 12 % of all cancer cases.

New screening methods based on tissue fluids such as blood or urine and greater individualisation of the screening are in demand, including the development of new methods for risk assessment.

Treatment and follow-up

Clinical studies are an essential part of developing and improving cancer treatment, and both projects that make use of well-known trial designs and the development of new designs can provide value for cancer patients. It could be, for example,

- Reuse approved drugs for a new indication that has no commercial interest - approved drugs are immediately available and well-explained concerning mechanisms of action and side effects
- Develop new trial designs that can make new treatments and technologies come into use more quickly by using
 - o Synthetic control groups, which are virtual control groups created from statistical models
 - o Hybrid control groups that combine different types of patients from earlier trials or registries
 - o Use of clinical registries to conduct clinical trials, including tools to randomise patients enrolled in registries and use of registries to collect relevant endpoints, including efficacy and safety
- Carry out studies that create synergy between biological, epidemiological, and clinical research to identify suitable drug candidates, test hypotheses about mechanisms of action and develop better treatment options
- Carry out studies regarding biomarkers with an emphasis on their implementation

Support can be donated for full or partial coverage of direct research-related expenses and the preparation of studies. Emphasis is placed on including, where possible, translational studies of patient material.

No support is provided for industry-sponsored studies.

Assessment

The applications will be assessed by The Danish Cancer Society's Scientific Committee – Biology & Clinic (KBVU-BK). The expected timeline of the assessment process is by the end of September 2024.

The Committee will focus on the project's quality, originality, and feasibility, among other things. It is a requirement that the results of the funded projects will be published in relevant scientific and professional journals.

Practical information

The applicant must meet the requirements defined in the Danish Cancer Society's Ethical Guidelines.

Support is subject to sufficient available Knæk Cancer 2024 funds. The organisation of the Knæk Cancer campaign is in week 43 in October.

The Danish Cancer Society's usual funding and accounting conditions will apply in case of funding. The conditions are available on our website - please see below.

Deadline

Thursday, 20 June 2024 at 15:00

The signature page must be signed and sent by e-mail to forskningsbevilling@cancer.dk

Application form

The application must be completed according to the "Funding possibilities and guidelines" via the electronic application form on our website www.cancer.dk/kc-midler.

For questions related to the application form, please contact funding coordinator Anne Mette Bak at amb@cancer.dk or 3525 7257.

The Danish Cancer Society
Funding & follow-up

